Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
ClinicalTrials.gov study NCT02536625. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
ClinicalTrials.gov study NCT06341894. IPD Sharing: NO. Countries: 1. Publications: 0.
The Effect of the Human Regenerator Jet Device on the Quality of Life of Adult Individuals [HR-QoL]
ClinicalTrials.gov study NCT07279272. IPD Sharing: NO. Countries: 1. Publications: 0.
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
ClinicalTrials.gov study NCT06680596. IPD Sharing: NO. Countries: 1. Publications: 0.
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT07180056. IPD Sharing: NO. Countries: 1. Publications: 0.
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
ClinicalTrials.gov study NCT06750848. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT06375707. IPD Sharing: YES. Countries: 1. Publications: 0.
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
ClinicalTrials.gov study NCT06299124. IPD Sharing: NO. Countries: 1. Publications: 0.
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06860529. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practic
ClinicalTrials.gov study NCT06625333. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06383767. IPD Sharing: NO. Countries: 1. Publications: 0.
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
ClinicalTrials.gov study NCT05569811. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
ClinicalTrials.gov study NCT03819010. IPD Sharing: YES. Countries: 2. Publications: 0.
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
ClinicalTrials.gov study NCT05645536. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
ClinicalTrials.gov study NCT04460430. IPD Sharing: NO. Countries: 2. Publications: 0.
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
ClinicalTrials.gov study NCT05153135. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
ClinicalTrials.gov study NCT05683418. IPD Sharing: NO. Countries: 2. Publications: 0.
A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endo
ClinicalTrials.gov study NCT04943497. IPD Sharing: NO. Countries: 1. Publications: 0.
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
ClinicalTrials.gov study NCT05411380. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
ClinicalTrials.gov study NCT07163481. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.